Completed trials

Cancer type Title Country
Breast cancer A phase Ib/II, multicenter, open-label study to evaluate the efficacy of AUY922 in combination with trastuzumab in patients with locally advanced or metasatatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-con SE
Breast cancer A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride Versus Placebo When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases Treated With Hormonal Treatment Backg DK
Breast cancer Intra-hepatic chemotherapy in patient with non-resectable liver metastases from breast cancer and limited extrahepatic disease DK
Breast cancer Phase Ib, open-label, multicenter dose-escalation study followed by an extension phase to evaluate the safety pharmacokinetics and activity of RO5479599 a glycoengineered antibody against HER3, administered incombination with pertuzumab and paclitaxel in DK
Breast cancer Phase Ib, Open-Label, Multicenter, Doseescalation Study followed by an Extension Phase to Evaluate the Safety, Pharmacokinetics and Activity of Ro5479599, a Glycoengineered Antibody Against Her3, Administered in combination with Pertuzumab and Paclitaxel DK
Breast cancer Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer SE
Colorectal cancer Assessmant of safety and immunogenicity of intradermal electroporation of tetwtCEA DNA in patients with colorectal cancer SE
Colorectal cancer Randomized Double blind Placebo Controlled Gross-over Phase II study on the effects of Lactobacillus Rhamnosus GC supplementation in patients on 1st Line Chemotherapy treatment for Metastatic Coloretctal Cancer- the "lactAXE"- trial FI
Colorectal cancer Treatment of Inoperable Colorectal Cancer With Electrochemotherapy Through an Endoscopic System DK
Esophageal cancer Follow up of Phase I study of radiotherapy and platinum-Fluouracil based chemotherapy with cetuximab in locally advanced esopgael cancer DK
Gastric cancer Phase I-II study of traztuzumab combined with docetaxel, oxaliplatin and capecitabine in advanced or metastatic gastic or cardia cancer DK
Glioblastoma BIBF1120 in patient with glioblastoma and progression after standard therapy /temozolomide and radiotherapy (group 1) or after bevacizumab based secondline therapy (group 2) DK
Glioblastoma DC-CAST-GBM NO
Glioblastoma Phase I dose escalation of anti-PlGF combined with bevacizumab 10 mg/kg every 2 weeks in recurrent GBM DK
Head and Neck cancer Boron neutron capture therapy (BNCT) for the treatment of inoperable head and neck cancer FI
Hematological malignancies A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 inPatients with Advanced Hematological Malignancies DK
Leukemia A Multicenter, Open-Label, Dose-Escalating Phase I Trial of the DNA-PK Inhibitor MSC2490484A in Subjects With Advanced Solid Tumors or Chronic Lymphocytic Leukemia DK
Leukemia A Phase II Multi-center, Open Label, Randomized Study to Assess Safety and Efficacy of Two Different Schedules of Oral LDE225 in Adult Patients With Relapsed/Refractory or Untreated Elderly Patients With Acute Leukemia NO
Lung cancer A multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment NO
Lung cancer A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment NO
Lung cancer A Phase 1b/2 study of docetaxel with or without buparlisib as second line therapy for patients with advanced or metastatic squamous non-small cell lung cancer SE
Lung cancer A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology DK
Lung cancer CAUY922A2206 NSCLC NO
Lung cancer Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination with Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects with Solid Malignancies and Deregulated FGF Pathway Signaling DK
Lymphoma Protocol I6F-MC-JJCA(c) A Phase 1 Study of LY3039478 in Patients with Advanced or Metastatic Cancer DK
Melanoma CA184025 Malign melanoma (inop. III and IV) NO
Melanoma CLGX818X2101 Locally advanced or mestastatic BRAF mutant melanoma NO
Melanoma DC-004 Unresectable metastases (Stage III or IV M1a-c-Malign melanoma) NO
Multiple diagnosis A Multicenter, Open-Label, Dose-Escalating Phase I Trial of the DNA-PK Inhibitor MSC2490484A in Subjects With Advanced Solid Tumors or Chronic Lymphocytic Leukemia DK
Multiple diagnosis C08-315-01 Transdermally accessible tumour NO
Multiple diagnosis Calcium Electroporation for the Treatment of Keloids DK
Multiple diagnosis Calcium Electroporation for Treatment of Cutaneous Metastases DK
Multiple diagnosis MOC31-PE Advanced mamma, lung, colorectal or prostate carcinoma NO
Multiple diagnosis Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MKMK)in Patients with Advanced Cancer NO
Myeloma A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma DK
Myeloma Daratumumab (anti-CD38) in refractory multiple myeloma, first in humans DK
Ovarian cancer A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies and Metastatic Breast Cancer DK
Ovarian cancer DC-006 Recurrent ovarian epithelial cancer NO
Ovarian cancer KCP-330-005A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients with Advanced Gynaecologic Malignancies DK
Pancreatic cancer Bay86-9766 And Gemcitabine in PAncreatic Cancer (BAGPAC) NO
Pancreatic cancer Treatment of pancreatic adenocarcinoma by combining contrast agent and gemcitabine under sonication. NO
Prostate cancer A Bioavailability Study of ODM-201 Formulations With a Safety and Tolerability Extension Component in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer FI
Skin cancer Combined treatment with Autologous Dendritic cells and T cells in patients with advanced Melanoma SE
Solide tumores A first-in-human Phase 1 dose excalation study of SAR428926 in patients with advanced solid tumors DK
Solide tumores A First-in-human, Multicenter, Open-label, Multiple Ascending Dose Phase I Study in Patients With Advanced Solid Tumors to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intratumorally Administered ADC-1013 DK
Solide tumores A phase 1/2 study of safety and efficacy of ulocuplumab combined with nivolumab in subjects with advanced or metastatic solid tumors FI
Solide tumores A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Patients With Metastatic and/or Locally Advanced Malignant HER3-Positive Solid Tumors DK
Solide tumores An Open-label multicenter dose escalation phase 1 study with an expansion phase to evaluate safety pharmacokinetics and therapeutic activity of RO6895882 an immunocytokine consisting of a variant of interleukin-2 (IL-2v) targeting carcinoembryonic antigen DK
Solide tumores An Open-label Non-randomised Multicentre Comparative Phase I Studyof the Pharmacokinetics Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients with Advanced Solid Tumours and Normal Renal Function or Renal Impairment DK
Solide tumores An open-label, multicohort, Phase II study of MPDL3280A in advanced solid tumors DK
Solide tumores CMEK162X2102 All solid tumors with BRAF or RAF mutation NO
Solide tumores Dose-escalating safety trial of tissue factor specific antibody drug conjugate (Humax®-TF-ADC) in patients with locally advanced and/or metastatic solid tumors known to express tissue factor DK
Solide tumores First study of intravenous catumaxumab (Removab) in patients with EpCam expressing epithelial solid tumors DK
Solide tumores Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Anti-Tumour Activity and Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients with Solid Cancer DK
Solide tumores Safety and pharmacokinetics of ODM-207 in patienst with selected advanced tumors; an open-label, non-randomosed, uncontrolled, multicentre, first-in-human study with cohort expansion FI
Solide tumores TWEAK-antibody in patients with Fn14 expressing solid tumors, first in humans study DK